SUPN Supernus Pharmaceuticals Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: SUPN

Price (delayed)

$44.63

Market cap

$2.59B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.51

Enterprise value

$2.43B

Sign up for free to view scoring metrics ?
Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 33

Supernus Pharmaceuticals, Inc. is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. The Company markets Trokendi XR® (extended-release topiramate) for ...

Highlights
The gross profit is up by 18% YoY and by 8% QoQ
Supernus Pharmaceuticals's revenue has increased by 16% YoY and by 8% from the previous quarter
The company's net income has shrunk by 147% YoY but it rose by 25% QoQ
The EPS has dropped by 145% year-on-year but it is up by 25% since the previous quarter
The debt is up by 15% year-on-year
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Website: http://www.supernus.com
Peers: UTHR ABT LLY BMY

Key stats

What are the main financial stats of SUPN

SUPN stock price

How has the Supernus Pharmaceuticals stock price performed over time
Intraday
1.35%
1 week
-4.74%
1 month
-8.23%
1 year
38.17%
YTD
-10.2%
QTD
-13.66%

Financial performance

How have Supernus Pharmaceuticals's revenue and profit performed over time
Revenue
$776.83M
Gross profit
$694.64M
Operating income
-$40.21M
Net income
-$29.02M
Gross margin
89.4%
Net margin
-3.7%
SUPN's operating income has plunged by 152% YoY and by 9% from the previous quarter
The company's net income has shrunk by 147% YoY but it rose by 25% QoQ
The company's operating margin has shrunk by 145% YoY
The net margin has dropped by 140% year-on-year but it is up by 31% since the previous quarter

Price vs fundamentals

How does SUPN's price correlate with its fundamentals

Growth

What is Supernus Pharmaceuticals's growth rate over time

Valuation

What is Supernus Pharmaceuticals stock price valuation
SUPN P/E details
P/E
N/A
P/B
2.39
P/S
3.31
EV/EBIT
N/A
EV/EBITDA
41.68
EV/Sales
3.13
The EPS has dropped by 145% year-on-year but it is up by 25% since the previous quarter
SUPN's price to book (P/B) is 18% more than its 5-year quarterly average of 2.0 but 2.1% less than its last 4 quarters average of 2.4
Supernus Pharmaceuticals's equity has increased by 4.5% YoY
Supernus Pharmaceuticals's revenue has increased by 16% YoY and by 8% from the previous quarter
The P/S is 13% above the 5-year quarterly average of 2.9 but 9% below the last 4 quarters average of 3.6

Efficiency

How efficient is Supernus Pharmaceuticals business performance
SUPN's return on invested capital has dropped by 164% year-on-year and by 5% since the previous quarter
The return on sales has dropped by 146% year-on-year but it is up by 7% since the previous quarter
The company's return on equity has shrunk by 144% YoY but it rose by 27% QoQ
The return on assets has dropped by 143% year-on-year but it has grown by 29% since the previous quarter

Dividends

What is SUPN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for SUPN.

Financial health

How did Supernus Pharmaceuticals financials performed over time
The company's total liabilities rose by 34% YoY and by 8% QoQ
The quick ratio has contracted by 30% YoY but it has grown by 3.4% from the previous quarter
The debt is 97% smaller than the equity
The debt is up by 15% year-on-year
Supernus Pharmaceuticals's equity has increased by 4.5% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.